I don't see it as myopic as just guides to understanding what niches the platform will probably fill; I agree that clinical apps (which put a high premium on speed) will dominate. There's also a huge opportunity for smaller genomics studies, given the smaller upfront cost & the fast turnaround.
In the current form, the cost isn't competitive with Illumina or SOLiD if you really want to pile up reads and bases, such as for de novo sequencing, whole genome resequencing or transcriptome profiling. But, I agree that when they succeed at a few rounds of revisions (if I get my act together, tomorrow's blog post will cover this) it really will be serious competition in those areas with Illumina and SOLiD.
In the current form, the cost isn't competitive with Illumina or SOLiD if you really want to pile up reads and bases, such as for de novo sequencing, whole genome resequencing or transcriptome profiling. But, I agree that when they succeed at a few rounds of revisions (if I get my act together, tomorrow's blog post will cover this) it really will be serious competition in those areas with Illumina and SOLiD.
Comment